NUP133 Antibody is available in multiple formats, including monoclonal and polyclonal variants, with diverse host species and specificities. Table 1 summarizes key characteristics of commercially available antibodies:
Reactivity: Most antibodies target human, mouse, and rat Nup133, with some cross-reactivity in Xenopus and yeast models .
Purification: Antibodies range from unpurified supernatant (e.g., OAPC00044) to affinity-purified forms (e.g., 12405-1-AP) .
Concentration: Typically 0.25–1 mg/mL, optimized for dilution in specific assays (e.g., IF: 1:50–1:100; WB: 1:1000–1:2000) .
NUP133 Antibody is employed in diverse experimental workflows:
Detection: Identifies Nup133 in whole-cell lysates or immunoprecipitated complexes.
Key Findings:
Localization: Visualizes Nup133 at nuclear pore complexes and kinetochores during mitosis .
Protocol:
RNA Export: Antibodies blocking Nup133 disrupt poly(A)+ RNA export without affecting protein transport .
Nuclear Pore Assembly: CRISPR-edited podocytes lacking Nup133 show defective pore assembly and cytoskeleton regulation .
Nup133 is integral to nuclear pore function and cellular processes. Key studies highlight its roles:
Structural Role: Nup133 anchors the Nup160 complex (Nup160, Nup96, Nup107) to the nuclear envelope, ensuring proper NPC formation .
Defective Assembly: Nup133 knockout in murine embryonic stem cells reduces Tpr-containing pores and disrupts nuclear basket integrity .
Functional Impact: Nup133 and Nup160 subunits are required for poly(A)+ RNA export. Dominant-negative fragments block mRNA export but spare protein import .
NUP133-Linked Nephropathy: Mutations in NUP133 cause steroid-resistant nephrotic syndrome (SRNS) by impairing podocyte transcriptome regulation and actin dynamics .
Pathogenic Mutations: Disease-associated variants reduce Nup133 protein levels or disrupt interactions with the Y-complex, leading to partial loss-of-function .
Isoform-Specific Roles: Nup133 isoform 2 is implicated in Th2 signaling, linking T-cell receptor activation to c-Maf transcription factor activity .
Table 2 contrasts antibody efficacy in key experimental systems: